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Abstract
Objective: To report a unique case of fluoxetine overdose leading to serotonin syndrome with auditory and
complex visual hallucinations. This case also demonstrates serotonin syndrome may mimic a Parkinsonian
syndrome, which is poorly described in the literature.
Case Summary: A 65-year-old gentleman, undergoing evaluation for possible Parkinsonian syndrome with
bradykinesia and rigidity presented to the emergency department with additional complaints of weakness, fatigue,
flushing, and complex visual and auditory hallucinations. Chart review revealed he was unintentionally overdosed
with fluoxetine to a total daily dose of 160 mg. Examination revealed tachycardia, diaphoresis, significant mydriasis,
and visual hallucinations. Initial workup was unremarkable. Poison control recommended discontinuation of the
fluoxetine and in follow up he reported resolution of all symptoms.
Discussion: This case describes serotonin syndrome as the result of chronic fluoxetine overdose masquerading
as a Parkinsonian syndrome. This patient also experienced auditory and visual hallucinations that resolved with
cessation of fluoxetine, adverse effects which are relatively uncommon. The likelihood the patient’s symptoms were
the result of fluoxetine intoxication is probable, as assessed by the Naranjo Adverse Drug Reaction (ADR)
probability scale.
Conclusions: Chronic fluoxetine overdose can lead to serotonin syndrome, as well as, several rare adverse
effects including a Parkinsonian syndrome, complex visual, and auditory hallucinations. A high index of suspicion is
necessary for diagnosis of serotonin syndrome, particularly in mild cases. Most cases can be prevented with careful
medication reconciliation.
Keywords: Fluoxetine; Selective Serotonin Reuptake Inhibitor
(SSRI); Serotonin syndrome; Complex visual hallucination; Auditory
hallucination; Parkinsonian; Adverse Drug Reaction (ADR)
Introduction
Serotonin Syndrome (SS) is characterized by a spectrum of changes
in mental status, neuromuscular dysfunction, and autonomic
instability. It is associated with increased serotonergic activity in the
central nervous system and is a potentially life threatening condition.
It is largely preventable by responsible prescribing practices and
proper patient education. A number of drugs from different classes are
implicated in the development of SS, including antidepressants such as
fluoxetine. Most cases are reported in patients taking more than one
serotonergic medication, however, overdose on a single agent can lead
to SS [1].
Case Description
A 65-year-old gentleman, undergoing outpatient neurology
evaluation for possible Parkinsonian syndrome for symptoms of
rigidity and bradykinesia presented to the emergency department with
additional complaints of six weeks of weakness, fatigue, flushing, and
complex visual and auditory hallucinations. His past medical history
was notable for depression. He received his medications for a mail
order pharmacy. Chart review revealed he was originally prescribed 20
mg fluoxetine tablets, taken as two tablets by mouth twice daily, which
was changed to 40 mg tablets unbeknownst to him. This resulted in
unintentional overdose with a total daily dose of 160 mg. The patient
denied deliberate overdose or suicidal ideation. He had no known
history of substance abuse.
Physical and mental status examination at the time of admission
revealed tachycardia, diaphoresis, significant mydriasis, and visual
hallucinations. His blood pressure was slightly elevated but stable.
Laboratory studies showed normal CBC, TSH, BMP, and LFTs. An
ECG was unchanged from prior exams with a QTc at the upper limit
of normal. Urine drug screen and serum ethanol levels were negative.
Serum fluoxetine or nor-fluoxetine levels were not obtained. Poison
control recommended discontinuation of the fluoxetine and
observation. With improving symptoms, he was discharged following
several days of observation. In follow up four weeks later, he reported
resolution of all symptoms, including rigidity and bradykinesia. He
was not restarted on any antidepressant medications. The likelihood of
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the patient’s symptoms being the result of fluoxetine intoxication is
probable, as assessed by the Naranjo Adverse Drug Reaction (ADR)
probability scale.
Discussion
Serotonin Syndrome is typically an iatrogenic phenomenon caused
by medications that affect serotonin transport, signaling, and
metabolism [1]. A high level of suspicion is necessary for diagnosis,
especially in mild cases [2,3]. The incidence of SS appears to be
increase in, [4-7] which may reflect increased use or availability of
drugs that affect serotonin or increasing provider awareness. Still,
many cases go unrecognized, and there is no national reporting
mechanism making the true incidence difficult to determine [4]. The
committee on identifying and preventing medication errors estimates
that adverse drug events cost at least $3.5 billion annually, many of
which are thought to be preventable in the ambulatory setting [8].
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Figure 1: Clinical Presentation of Serotonin Syndrome [9]
The clinical presentation of SS is highly variable. However, the
diagnosis is suggested by the constellation of autonomic instability,
neuromuscular signs, and mental status changes in the setting of
serotonergic medications (Figure 1). Several diagnostic criteria have
been developed for use in clinical practice including sternbach’s
criteria and the hunter serotonin toxicity criteria. Diagnosis via the
Hunter criteria is based on decision rules requiring the presence of a
feature or group of features, such as inducible clonus with agitation or
tremor with hyperreflexia (Figure 2) [10]. Sternbach’s requires at least
three of ten clinical features with a recent addition or increase in an
offending medication (Figure 3) [11]. Hunter’s Criteria may be a more
useful diagnostic tool, as it is both more sensitive and specific than
Sternbach’s [4].
Onset of SS is usually rapid, often within six hours of medication
ingestion or dose changes. However, patients with mild serotonin
syndrome may present with subacute or chronic symptoms [2].
Medications from many classes can cause SS when taken in
combination [4,12]. Selective Serotonin Reuptake Inhibitors (SSRIs)
are known to cause serotonin syndrome when taken alone in large
overdoses [13]. However, this case highlights that relatively mild,
chronic overdose with fluoxetine may also lead to SS. Fluoxetine alone
leading to SS at therapeutic or slightly supra-therapeutic doses is
reported in only a few cases in the literature [14,15]. Patient specific
factors can also increase risk for developing the syndrome. Endothelial
damage mediated by hypertension, diabetes, and atherosclerosis, may
lead to decreased production of MAO-A [2] or nitrous oxide [16]
increasing the risk of SS through up regulation of serotonin signaling.
Medications that inhibit the cytochrome P450-2D6 or 3A4 enzymes
used in combination with an SSRI can increase the risk for SS [4].
Fluoxetine, in particular, has a long half-life and is a potent inhibitor
of the CYP2D6 enzyme, which can increase the production of
serotonin metabolites [2]. Interestingly, our patient was on long-term
oxy codone therapy, which has been shown to increase release of
serotonin in the forebrain and may increase the risk of SS [17,18].
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Figure 2: The Hunter Serotonin Toxicity Criteria [10]
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Figure 3: The Sternbach Criteria: Suggested Diagnostic Criteria for
Serotonin Syndrome [11]
The differential diagnosis includes infection, metabolic disorders,
anticholinergic toxicity, dopaminergic or sympathomimetic overdose,
malignant hyperthermia, neuroleptic malignant syndrome, heat
stroke, serotonin-secreting tumor, and substance use or withdrawal
[2,4]. The initial evaluation should focus on investigating these
possibilities. A complete medication history that includes all non
prescription medications, supplements, and illicit drugs should be
obtained. Laboratory and imaging studies may be necessary to evaluate
for infection or endogenous sources of hormone or neuropeptide
excess. First-line treatment includes discontinuation of the suspected
agent and supportive care. Most mild cases resolve in one to three days
and do not require hospitalization. Patients with more severe
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symptoms should be monitored in an inpatient setting. Agitation and
tremor can be treated with benzodiazepines. Patients with life
threatening symptoms may require critical care including sedation,
neuromuscular paralysis, and intubation. Cyprohepatidine, a
serotonin 2A antagonist, is often widely used despite a lack of strong
evidence for its effectiveness in SS [4].
This case also illustrates an uncommon side effect of SSRI
medications. Though SSRIs are known to improve psychotic features
in some patients with schizophrenia and psychotic depression, this
case highlights paradoxical development of hallucinations with
fluoxetine [19]. Auditory and Complex Visual Hallucinations (CVH)
are rare adverse effects with ingestion of SSRIs, including fluoxetine,
sertraline, fluvoxamine, paroxetine, and citalopram that are most often
presented as case reports in the literature [19-23]. Several mechanisms
have been proposed to explain the development of hallucinations in
this setting. Postsynaptic 5-HT2 and 5-HT3 receptor signaling may
play a role in the ventral striate and mesolimbic regions of the brain,
with signaling mediated by dopamine and serotonin [19,22]. In the
setting of CVH, another proposed mechanism is an imbalance
between serotonin and acetylcholine signaling, with relative serotonin
excess and acetylcholine deficit [20,22]. Finally, stimulation of high
affinity sigma receptors in the hippocampus may be involved.
Interestingly, CVH have also been reported upon discontinuation of
fluoxetine therapy [18].
Additionally, this case suggests serotonin syndrome may
masquerade as a Parkinsonian syndrome. Our patient’s Parkinsonian
symptoms coincided with increased fluoxetine dose and resolved
following its discontinuation. Parkinsonism in the setting of serotonin
syndrome is poorly described in the literature.
Conclusions
Serotonin syndrome is a potentially life threatening condition with
a highly variable clinical presentation, which may include
hallucinations and mimic a Parkinsoninan syndrome. The increasing
number of patients taking serotonergic medications makes provider
recognition important to avoid unnecessary testing and potential
morbidity and mortality. Most cases can be prevented with careful
medication reconciliation.
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